FDA Extends Review of Exelixis Colorectal Cancer Combo to March 2027
FDA adds three months to its review of Exelixis’ zanzalintinib plus Tecentriq for metastatic colorectal cancer after a major amendment.
/ 4 items
#EXEL↓
BMO Capital Initiates Coverage on 7 Biotech Stocks: Outperform Ratings for ALNY, ASND, BMRN & More
BMO Capital starts coverage on ALNY, ASND, BMRN, CATX & more with Outperform ratings and price targets. See full analyst insights and targets.
Kura Oncology Stock Surges as Darlifarib + Cabozantinib Shows Strong Results in Tough Kidney Cancer Cases
Kura Oncology’s combo drug shrank kidney tumors in early trial, controlled cancer in most patients, stock jumped.
William Blair Maintains Buy Rating on Exelixis Following Positive Cancer Trial Results, Despite Safety Concerns
William Blair analyst Andy Hsieh reaffirms Buy rating on EXEL stock after Phase III trial shows zanzalintinib combination therapy improves survival in metastatic colorectal cancer patients.